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Introduction
Decoy receptor 3 (DcR3) is a soluble tumor necrosis factor receptor (TNFR) overexpressed in various tumors, including lung cancers, 1 gastrointestinal tract tumors, 2 virus-associated lymphomas, 3 malignant gliomas, 4 and pancreatic cancers. 5 DcR3
suppresses the activation and differentiation of dendritic cells (DCs), 6 macrophages, 7 as well as enhances osteoclast differentiation, 8 and angiogenesis. 9 Moreover, DcR3 is shown to sensitize cells to TRAIL-induced apoptosis. 10 Moreover, almost all serum DcR3-positive individuals (98.8%, 82 out of 83 cases) had malignancy, 11 and DcR3 overexpression was found to be associated with shortened duration of overall survival in cancer patients. 12 Therefore, DcR3 is an important immunosuppressive factor in promoting tumor growth in cancer patients.
DCs are the most potent antigen-presenting cells capable of priming tumor-specific T cells. The sentinel lymph node (SLN) is the first draining lymph node from the area in which a tumor is located, and the numbers of DC are reduced in SLNs from some cancer patients. 13 In our previous study, we found the total numbers of CD14 + monocyte-derived DCs decreased significantly when incubated with DcR3. 6 Thus, we are interested to know whether DcR3 is one of the tumor-associated factors that affect DC survival, as well as to dissect the signaling cascades leading to DC apoptosis.
Apart from neutralizing endogenous TL1A to promote angiogenesis, the pleiotropic effects of DcR3 described above are independent of its interaction with three known ligands -FasL, LIGHT, and TL1A. Moreover, recombinant protein comprising the heparin binding domain (HBD) of DcR3 and Fc portion of human IgG 1 (HBD.Fc), which is unable to interact with LIGHT, FasL or TL1A, has same effect as DcR3.Fc to modulate
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PKC is a family of serine/threonine kinases grouped into three subfamilies based on their structures and cofactors required for activation: the conventional (α, βI, βII and γ), the novel (δ, ε, η, and θ), and the atypical (ζ and λ/ι) isoforms. 16 The conventional PKCs are activated by diacylglycerol and phosphatidylserine in the presence of Ca 2+ . The novel PKCs are activated by diacylglycerol and phosphatidylserine but are independent of Ca 2+ , and the atypical PKCs appear to respond only to phosphatidylserine. It is interesting to note that the selective inhibitor of PKC-δ, rottlerin, and a dominant-negative mutant of PKC-δ attenuate apoptosis induced by phorbol ester, H 2 O 2 , UV radiation, taxol and etoposide, 17, 18 indicating that PKC-δ is involved in cell apoptosis. Previously, we have shown that DcR3.Fc (3 µg/ml) modulates CD14 + monocyte-derived DC differentiation. 6 Recently, we further observed that a higher concentration of DcR3.Fc (10 µg/ml) induces DC apoptosis. Therefore, we compared the effects of DcR3.Fc and HBD.Fc on the survival of DCs, and investigated whether PKC was involved in DcR3-mediated DC apoptosis.
Here we report that both DcR3.Fc and HBD.Fc induced DC apoptosis by activating JNK to upregulate DR5 and trigger death signaling cascades. Moreover, PKC-δ-specific inhibitor rottlerin suppressed JNK activation and blocked DcR3-induced DC apoptosis.
Since recombinant HBD.Fc has a similar effect as DcR3.Fc, this indicates that cross-linking of HSPG on DCs can activate PKC-δ specifically to induce DC apoptosis.
This elucidates a novel mechanism of DcR3 to regulate cell apoptosis, and cross-linking 
Materials and Methods

Antibodies and reagents
The sources of mAbs are as follows: anti-DR4, anti-DR5, anti-JNK1, anti-phospho-JNK, anti-caspase-3 (R&D Systems, Minneapolis, MN); anti-Fas 
Cell cultures
Human peripheral blood (PBL) samples were obtained from healthy donors (Red Cross society, Taiwan) according to institutional guidelines of the National Yang-Ming University, Taipei, Taiwan. Monocyte-derived DCs 6 and macrophages 7 were cultured from CD14 + monocytes from human PBL as described, and were cultured in RPMI 1640
(Life Technologies, Gaithersburg, MD) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Life Technologies) at 37°C in 5% (v/v) CO 2 as previously described. 
Detection of apoptotic cells
The morphology of apoptotic DC was analyzed by incubating cells with 0.1% trypan blue and 0.2 µg/mL Hoechst 33258 in phosphate-buffered saline (PBS) for 3 minutes at room temperature, and viable cells in 10 randomly chosen fields were counted at 200-fold magnification using phase-contrast and immunofluorescent microscopy. 
Surface staining and mitochondrial membrane potential
The surface markers of monocyte-derived DCs were determined by flow cytometry analysis as previously described. 6 To measure mitochondrial membrane potential, cells reverse: 5' GAAGATGGT GATGGGATTTC 3') were used as reference primers.
Relative quantification was performed using the Light Cycler ® Software.
Analysis of caspase activity
Cell extracts were prepared by freezing and thawing in lysis buffer as previously
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 9 described. 19 Cell lysates (50 µg) were diluted in 500 µl of ICE buffer (100 mM HEPES-KOH buffer, pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM dithiothreitol, 0. (R&D Systems) and incubated at 30°C for 60 minutes. Fluorescence intensity was measured using a fluorescence spectrophotometer (Hitachi, Tokyo, Japan).
Measurement of PKC-δ activity
Cell extracts (300 µg) were incubated with anti-PKC-δ antibody, followed by 
Immunoblot and immunoprecipitation analysis
Cell lysates were prepared for immunoblotting as described previously. 19 For DR5 DISC analysis, DcR3.Fc-treated cells were lysed in lysis buffer (1% NP-40, 20 mM
Tris-HCl/pH 7.5, 150 mM NaCl, 10% glycerol). Cell lysates were centrifuged at 10,000 g for 10 minutes at 4°C, and supernatants were incubated for 16 hours with Sepharose beads (Amersham Biosciences) adsorbed with anti-DR5 antibody. Beads were then washed four times in cold lysis buffer, and immunoprecipitates were fractionated on SDS-PAGE before being subjected to immunoblotting. 
Statistical analysis
Student's t test (paired data) was used to analyze the statistical significance of differences.
Results
Apoptosis of DC induced by DcR3.Fc and HBD.Fc
Heparan sulfate proteoglycans (HSPGs) have been shown to be ligands for DcR3, and knockdown of syndecan-2 and CD44v3, two abundant HSPGs on macrophages and DC, abolished DcR3-mediated PKC activation in macrophages. 14 1A) . In contrast, macrophages did not respond to DcR3.Fc-mediated cell apoptosis under the same conditions ( Figure   S1 ). The apoptosis of DC was further confirmed by subG1 peak analysis ( , and Z-AEVD-FMK (caspase-10 inhibitor) (Fig 2A, upper panel) . This suggested that caspases are crucial in DcR3.Fc-mediated cell death. To further confirm this observation, caspase substrates were used to quantify caspase activities (Fig 2A, lower panels). The activities of caspase-8 and caspase-10 increased at 12 and 36 hours after DcR3.Fc treatment. Moreover, caspase-2, which has been reported to process procaspase-8 to sensitize TRAIL-mediated apoptosis, 20 was also activated with similar kinetics. Caspase-3 was slightly activated at 12 hours, and reached peak at 36 hours post treatment (Fig 2A & 2B , lower panels). It is interesting to note that activation of caspase-8 correlated with the cleavage of Bid, a caspase-8 substrate, at 12 hours post treatment (Fig. 2B, upper panel) . Moreover, the kinetics of caspase-3 activation correlated with cleavage of the caspase-3 substrate, poly (ADP-ribose) polymerase (PARP) (Fig. 2B, lower panel) . This demonstrated that caspases play essential roles in DcR3.Fc-mediated cell death.
It has been reported that Bid relays the apoptotic signal from the cell surface to the mitochondria. After cleavage, truncated Bid translocates to mitochondria, disrupts the mitochondrial membrane potential (Ψm) and, thereby, triggers cytochrome c release. 20 To investigate the mitochondrial function during DcR3.Fc and HBD.Fc treatment, JC-1 (Fig. 2C ). An MTT assay was used to investigate further the kinetics of apoptosis over 72 hours. We found that the number of apoptotic cells increased sharply from 24 hours to 72 hours when cells were treated with either DcR3.Fc or HBD.Fc (Fig. 2D) . The sequential activation of caspases and downregulation of membrane potential suggests that activation of the apoptosis-initiating caspases (caspase-2, -8 and -10) leads to disruption of the mitochondrial membrane potential and activation of caspase-3.
PKC and MAPK are involved in DcR3 -mediated cell death
Cross-linking of syndecan 2 and CD44v3, two abundant HSPGs on macrophages and DCs, by DcR3.Fc and HBD.Fc has been shown to activate PKC to induce cell adhesion in myeloid cells.
14 To investigate whether PKC is involved in DcR3-mediated DC apoptosis, DCs were co-incubated with various PKC inhibitors in the presence of DcR3.Fc or HBD.Fc. As shown in Fig. 3A , the PKC-δ-selective inhibitor rottlerin suppressed DC apoptosis, while Ro-32-0432 (PKC-α inhibitor) and a broad-spectrum PKC inhibitor (safingol) had no protective effect. In vitro kinase assay further demonstrated that DcR3.Fc and HBD.Fc were able to activate PKC-δ (Fig. 3B ). This observation suggested that cross-linking of HSPG could activate PKC-δ to trigger downstream apoptotic signal in DCs.
MAPKs have been reported to regulate apoptosis and are involved in DcR3.Fc-induced signals. 8 Among the MAPK inhibitors tested, JNK inhibitor (SP600125) was the most potent (p=0.008) in inhibiting DcR3.Fc-mediated cell death, while p38
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MAPK inhibitor (SB203580) also had a mild (p=0.049) inhibitory effect (Fig. 3C) . This was in accord with the observation that JNK was phosphorylated by 120 minutes after treatment (Fig. 3D) . Moreover, JNK phosphorylation was suppressed by the PKC-δ inhibitor rottlerin (Fig. 3E) , indicating that JNK activity was regulated by PKC-δ.
Since caspase activation occurred later than JNK phosphorylation, we further asked whether caspase activation is regulated by JNK. As shown in Figure 3F, (Fig. 4B) . To further understand whether upregulation of DR5 lead to cell apoptosis, we analyzed the formation of a death-inducing signaling complex (DISC) by immunoprecipitating DR5 to detect the presence of FADD and activated caspase-8 in the immunocomplex. The kinetic study demonstrated that both FADD and activated caspase-8 were detected in the DISC 9 hours and 12 hours post DcR3.Fc treatment (Fig. 4C) , and this demonstrated that DcR3.Fc-upregulated DR5 recruits FADD, which then activates caspase-8.
It has been shown that JNK is involved in DR5 upregulation by bile acid. 22 Since JNK activation (2 hours post treatment) occurred earlier than upregulation of DR5 (8 hours post treatment), we examined whether JNK and other MAP kinases are involved in DcR3-mediated DR5 upregulation. As shown in Figure 4D , JNK inhibitor (SP600125) suppressed the upregulation of DR5, while both p38 MAPK inhibitor (SB203580) and ERK inhibitor (PD98059) had no effect on DR5 upregulation (Fig. 4D ). This observation demonstrates that DcR3-induced DR5 expression is regulated by JNK. Therefore, we concluded that DcR3.Fc activates JNK to upregulate the expression of DR5, which then recruits FADD and activates caspase-8 to trigger apoptotic signaling cascades in DCs. Interestingly, DcR3.Fc-induced apoptosis (57%) was further increased by exogenous TRAIL (72%) as revealed by annexin V/7-AAD double staining (Fig. 5A) . PI staining to detect the percentage of apoptotic cells in subG1 peak (Fig. 5B) Therefore, we concluded that upregulation of DR5, but not Fas, induces the formation DR5 DISC which, thereby, increases DC susceptibility to TRAIL-mediated apoptosis. and LY379196 (PKC-βII inhibitor) were used to address this question. However, none of these inhibitors can increase the survival rate of DcR3-treated DC ( Figure S3 ). This further confirms the important role of PKC-δ in DcR3-mediated DC apoptosis. Since different PKC isoforms can either promote cell survival or induce cell death in different lineages, 16 pan-PKC inhibitor may block both pro-and anti-apoptotic PKC isoforms, thus it would be difficult to observe the protective effect of pan-PKC inhibitor, such as Safingol, on DcR3-induced apoptosis (Fig. 3A) . This argument is further supported by the observation that other broad-spectrum PKC inhibitors (including Ro-31-8220, GF-109203X, and Gö 6983), also fail to protect DCs from DcR3-mediated apoptosis ( Figure S3 ).
DcR3-mediated apoptosis is enhanced by exogenous TRAIL
It has been reported that PKC-δ activation is upstream of JNK activation in DNA damage-induced apoptosis. 17 This is in accord with our observation that JNK activation (60 min after DcR3.Fc treatment) occurs later than PKC activation (10 min after DcR3.Fc treatment) (Fig. 3D) , and JNK phosphorylation is suppressed by the PKC-δ inhibitor rottlerin (Fig. 3E) . Moreover, JNK has been reported to be involved in DR5 upregulation by bile acid, 24 buthionine sulfoximine, 25 and methyl-2-cyano-3,12-dioxooleana-1 treatment, 26 even though the underlying mechanism is still to be determined. In this study,
we demonstrate that the cross-linking of HSPGs by HBD.Fc and DcR3.Fc upregulates DR5 expression to induce the formation of DR5 DISC. Since JNK inhibitor downregulates DR5 expression (Fig. 4D) and inhibits caspase-8 activity (Fig. 3F) , this demonstrates that JNK-mediated apoptosis occurs through DR5 DISC formation in DcR3.Fc-treated DCs. The role of DR5 in DC apoptosis is further supported by the observation that DcR3.Fc increases DC susceptibility to exogenous TRAIL-induced apoptosis ( Fig. 5A and 5B). Since DcR3. The expression of DcR3 in cancer cells seems to be correlated with poor prognosis in cancer patients. We randomly selected 100 specimens of colon adenocarcinoma, and followed up the survival rate of patients based on the presence or absence of DcR3. The long term survival rate of DcR3-positive group is shorter than DcR3-negative group under the same treatment protocol significantly (p<0.001, unpublished data), and this suggests that DcR3 might become a valuable marker to monitor cancer progression in the future. For personal use only. on . by guest
